Pages that link to "Q28586173"
Jump to navigation
Jump to search
The following pages link to Nonredundant function of phosphodiesterases 4D and 4B in neutrophil recruitment to the site of inflammation (Q28586173):
Displaying 50 items.
- Phosphodiesterase 4D, cAMP specific (Q21496052) (← links)
- Differential expression and function of phosphodiesterase 4 (PDE4) subtypes in human primary CD4+ T cells: predominant role of PDE4D (Q24301560) (← links)
- Mdm2 directs the ubiquitination of beta-arrestin-sequestered cAMP phosphodiesterase-4D5 (Q24316484) (← links)
- Gene expression analysis reveals early changes in several molecular pathways in cerebral malaria-susceptible mice versus cerebral malaria-resistant mice (Q24646192) (← links)
- PDE4 inhibitors: current status (Q24651926) (← links)
- Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors (Q27647620) (← links)
- Keynote review: phosphodiesterase-4 as a therapeutic target (Q28279487) (← links)
- Prenatal environmental exposures, epigenetics, and disease (Q28391853) (← links)
- Mice deficient in phosphodiesterase-4A display anxiogenic-like behavior (Q29393932) (← links)
- Phosphodiesterase 4D and 5-lipoxygenase activating protein in ischemic stroke (Q30445412) (← links)
- Development of a high throughput screen for allosteric modulators of melanocortin-4 receptor signaling using a real time cAMP assay (Q30466708) (← links)
- Mapping binding sites for the PDE4D5 cAMP-specific phosphodiesterase to the N- and C-domains of beta-arrestin using spot-immobilized peptide arrays (Q33272818) (← links)
- Elevated cyclic AMP and PDE4 inhibition induce chemokine expression in human monocyte-derived macrophages (Q33564601) (← links)
- Phosphodiesterase Inhibitors as a Therapeutic Approach to Neuroprotection and Repair (Q33624262) (← links)
- Aging-related hyperinflammation in endotoxemia is mediated by the alpha2A-adrenoceptor and CD14/TLR4 pathways (Q33808323) (← links)
- Effects of phosphodiesterase 4 inhibition on bleomycin-induced pulmonary fibrosis in mice (Q33895012) (← links)
- Advances in targeting cyclic nucleotide phosphodiesterases (Q34139490) (← links)
- Genome-wide association study of chemotherapeutic agent-induced severe neutropenia/leucopenia for patients in Biobank Japan. (Q34343197) (← links)
- Phosphodiesterase 4B is essential for TH2-cell function and development of airway hyperresponsiveness in allergic asthma (Q34409716) (← links)
- Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice (Q34582255) (← links)
- Cyclic nucleotide phosphodiesterases: important signaling modulators and therapeutic targets (Q34765802) (← links)
- A selective phosphodiesterase-4 inhibitor reduces leukocyte infiltration, oxidative processes, and tissue damage after spinal cord injury. (Q35040399) (← links)
- Contribution of mammary epithelial cells to the immune response during early stages of a bacterial infection to Staphylococcus aureus. (Q35093057) (← links)
- Cross-talk between PKA-Cβ and p65 mediates synergistic induction of PDE4B by roflumilast and NTHi (Q35377816) (← links)
- Association between phosphodiesterase 4D (PDE4D) SNP 87 and ischemic stroke: a meta-analysis (Q35479293) (← links)
- The unrecognized effects of phosphodiesterase 4 on epithelial cells in pulmonary inflammation (Q35536563) (← links)
- A chemoattractant-mediated Gi-coupled pathway activates adenylyl cyclase in human neutrophils (Q35613540) (← links)
- Assessment of cellular mechanisms contributing to cAMP compartmentalization in pulmonary microvascular endothelial cells. (Q35849189) (← links)
- Postinjury treatment with rolipram increases hemorrhage after traumatic brain injury (Q36162694) (← links)
- Cyclic nucleotide phosphodiesterases as targets for treatment of haematological malignancies (Q36334968) (← links)
- Therapeutic benefits of phosphodiesterase 4B inhibition after traumatic brain injury (Q36380305) (← links)
- Phosphodiesterase isoform-specific expression induced by traumatic brain injury. (Q36446011) (← links)
- Traumatic Brain Injury Upregulates Phosphodiesterase Expression in the Hippocampus. (Q36548551) (← links)
- Intracellular targeting of phosphodiesterase-4 underpins compartmentalized cAMP signaling (Q36597940) (← links)
- Phosphodiesterases regulate airway smooth muscle function in health and disease (Q36820316) (← links)
- Attenuation of TNF production and experimentally induced inflammation by PDE4 inhibitor rolipram is mediated by MAPK phosphatase-1. (Q37046760) (← links)
- Anxiogenic-like behavioral phenotype of mice deficient in phosphodiesterase 4B (PDE4B). (Q37308995) (← links)
- Dual PDE3/4 inhibitors as therapeutic agents for chronic obstructive pulmonary disease (Q37332621) (← links)
- No Association Between Single-Nucleotide Polymorphism 56 (SNP56) in Phosphodiesterase 4D (PDE4D) Gene and Susceptibility to Ischemic Stroke: A Meta-Analysis of 15 Studies (Q37372158) (← links)
- The novel distribution of phosphodiesterase-4 subtypes within the rat retina (Q37415385) (← links)
- PDE4 inhibitors - a review of the current field (Q37425642) (← links)
- Phosphodiesterase 4D single-nucleotide polymorphism 83 and cognitive dysfunction in carotid endarterectomy patients (Q37604267) (← links)
- Targeting cancer with phosphodiesterase inhibitors (Q37650389) (← links)
- Clinical and molecular genetics of the phosphodiesterases (PDEs). (Q37657841) (← links)
- Mammalian Cyclic Nucleotide Phosphodiesterases: Molecular Mechanisms and Physiological Functions (Q37870035) (← links)
- Pharmacology, Clinical Efficacy, and Tolerability of Phosphodiesterase-4 Inhibitors: Impact of Human Pharmacokinetics (Q37893057) (← links)
- Dual PDE3/4 and PDE4 inhibitors: novel treatments for COPD and other inflammatory airway diseases. (Q38187182) (← links)
- Phosphodiesterase inhibitors as therapeutics for traumatic brain injury (Q38243490) (← links)
- Chloroquine rescues A549 cells from paraquat-induced death (Q38855451) (← links)
- RNA silencing identifies PDE4D5 as the functionally relevant cAMP phosphodiesterase interacting with beta arrestin to control the protein kinase A/AKAP79-mediated switching of the beta2-adrenergic receptor to activation of ERK in HEK293B2 cells. (Q40395764) (← links)